TNFRSF1B and neoplasm: To further assess the potential relationship of TNFR2 signaling on the state of the immune-suppressive tumor environment, and to predict the response of patients to the treatment with ICIs, we evaluated the expression of immune-checkpoint–relevant gene markers of SIGLEC15, TIGIT, CD274 (PD-L1), HAVCR2, PDCD1 (PD-1), CTLA4, LAG3, and PDCD1LG2 (PD-L2) (31, 32).